ArticlePLoS biology2005
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.
Article in PLoS biology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Nigrostriatal dopaminergic vulnerability in Parkinson's disease: Neuroprotective strategies.Neural regeneration research · 2026Article
- The Effects of Tyrosine Hydroxylase Blockade in Mice Lacking the Norepinephrine Transporter (NET-KO Mice).International journal of molecular sciences · 2026Article
- Alpha-methyl-para-tyrosine and amphetamine ameliorate hyperactivity in a novel mouse model of dopamine transporter deficiency syndrome.EMBO molecular medicine · 2026Article
- Therapeutic strategies for colorectal cancer: antitumor efficacy of dopamine D2 receptor antagonists.Toxicological research · 2024Review
- Prospects of Electrocorticography in Neuropharmacological Studies in Small Laboratory Animals.Brain sciences · 2024Review
- Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists.Biomolecules · 2023Article
- Alterations in Serotonin Neurotransmission in Hyperdopaminergic Rats Lacking the Dopamine Transporter.Biomedicines · 2023Article
- Alteration of Postural Reactions in Rats with Different Levels of Dopamine Depletion.Biomedicines · 2023Article
- Dopamine Transporter Deficient Rodents: Perspectives and Limitations for Neuroscience.Biomolecules · 2023Review
- Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation.Frontiers in behavioral neuroscience · 2023Review
- Inhibition of PDE10A in a New Rat Model of Severe Dopamine Depletion Suggests New Approach to Non-Dopamine Parkinson's Disease Therapy.Biomolecules · 2022Article
- AKT inhibition in the central nervous system induces signaling defects resulting in psychiatric symptomatology.Cell & bioscience · 2022Article
- Dusp26 phosphatase regulates mitochondrial respiration and oxidative stress and protects neuronal cell death.Cellular and molecular life sciences : CMLS · 2022Article
- A role for cortical dopamine in the paradoxical calming effects of psychostimulants.Scientific reports · 2022Article
- A Century Searching for the Neurons Necessary for Wakefulness.Frontiers in neuroscience · 2022Review
- Review
- The effect of low dose amphetamine in rotenone-induced toxicity in a mice model of Parkinson's disease.Iranian journal of basic medical sciences · 2020Article
- β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.Cell · 2020Article
- Cancer and the Dopamine DThe Journal of pharmacology and experimental therapeutics · 2019Review
- Integrated analysis of the critical region 5p15.3-p15.2 associated with cri-du-chat syndrome.Genetics and molecular biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Brain dopamine is critically involved in movement control, and its deficiency is the primary cause of motor symptoms in Parkinson disease. Here we report development of an animal model of acute severe dopamine deficiency by using mice lacking the dopamine transporter. In the absence of transporter-mediated recycling mechanisms, dopamine levels become entirely dependent on de novo synthesis. Acute pharmacological inhibition of dopamine synthesis in these mice induces transient elimination of striatal dopamine accompanied by the development of a striking behavioral phenotype manifested as severe akinesia, rigidity, tremor, and ptosis. This phenotype can be reversed by administration of the dopamine precursor, L-DOPA, or by nonselective dopamine agonists. Surprisingly, several amphetamine derivatives were also effective in reversing these behavioral abnormalities in a dopamine-independent manner. Identification of dopamine transporter- and dopamine-independent locomotor actions of amphetamines suggests a novel paradigm in the search for prospective anti-Parkinsonian drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.